Belgium· BE-AMP-SAM120617-00
Aspegic 100 mg
A acetylsalicylic acid product containing acetylsalicylate lysine, registered in Belgium by Substipharm. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Acetylsalicylic acid is registered in 13 of 19 countries.
Countries holding a registration under ATC N02BA01 (acetylsalicylic acid), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Acetylsalicylic acid · ATC N02BA01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of acetylsalicylic acid costs, country by country.
Normalised to the WHO defined daily dose (3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Acetylsalicylic acid · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$2.31
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Acetylsalicylate Lysine
- Manufacturer
- Substipharm
- Country
- Belgium (BE)
- ATC code
- N02BA01
- ATC class
- Acetylsalicylic acid
- Defined daily dose
- 3 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb1652049
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
832 interactions on record for acetylsalicylic acid.
Graded by severity as the source publishes them — 55 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Acetylsalicylic acid · interactions on record
832 records
- 55 severe
- 246 moderate
- 39 minor
- 429 info
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
63 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Acetylsalicylic acid in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/893f3b99-3670-477f-947f-9bdb4e6280ca GET /v1/drugs/893f3b99-3670-477f-947f-9bdb4e6280ca?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for oral solution",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Aspegic 100 mg",
"name_fr": "Aspegic 100 mg",
"name_nl": "Aspegic 100 mg",
"amp_code": "SAM120617-00",
"strengths": [
"180.0000",
"180.0000",
"100.0000",
"100.0000"
],
"pack_count": 3,
"substances": [
"Acetylsalicylate Lysine",
"Acetylsalicylic Acid",
"Lactose"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Acetylsalicylic Acid",
"authorisation_numbers": [
"BE120617"
]
}See everything about acetylsalicylic acid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.